Natalia Colocci, M.D., Ph.D.
Investigator
Natalia Colocci, MD, PhD, is a board-certified medical oncologist at Palo Alto Medical Foundation and serves as Executive Medical Director of the GI/Cancer Care Service Line. She has been a practicing oncologist with Palo Alto Foundation Medical Group since 2006 and also serves as Medical Director of Oncology.
Dr. Colocci earned her PhD in Chemistry from the California Institute of Technology and her MD from Harvard Medical School. She completed her internal medicine residency, chief residency, and oncology fellowship at Stanford University Medical Center.
Her clinical and research interests include breast, colorectal, lung, prostate cancers, lymphoma, and blood disorders. She is actively involved in clinical research and serves as a principal investigator on multi-cancer early detection studies.
Dr. Colocci holds multiple leadership roles within Sutter Health, including membership on key oncology and therapeutics committees, and is committed to advancing high-quality, patient-centered cancer care.
Publications
- Dillon EC, Meehan A, Nasrallah C, Lai S, Colocci N, Luft H.Am J Hosp Palliat Care. 1049909120969202. doi: 10.1177/1049909120969202. Online ahead of print.2020 Oct 28
Clinical trials
- Clinical trial
Adjuvant Breast NRG-BR009
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
Status: Open to Enrollment
- Clinical trial
Advanced Breast Cancer HR+ HER2- WO45654
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Status: Open to Enrollment
A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Status: Open to Enrollment
- Clinical trial
Cancer Early Detection REACH
REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity
Status: Open to Enrollment
- Clinical trial
Metastatic 1st Line Non-Small Cell Lung Cancer HARMONi-7
A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression
Status: Open to Enrollment